Proteomic profiling across breast cancer cell lines and models

被引:0
作者
Marian Kalocsay
Matthew J. Berberich
Robert A. Everley
Maulik K. Nariya
Mirra Chung
Benjamin Gaudio
Chiara Victor
Gary A. Bradshaw
Robyn J. Eisert
Marc Hafner
Peter K. Sorger
Caitlin E. Mills
Kartik Subramanian
机构
[1] Harvard Medical School,Laboratory of Systems Pharmacology, Program in Therapeutic Science
[2] The University of Texas MD Anderson Cancer Center,Department of Experimental Radiation Oncology
[3] IGBMC,Department of Oncology Bioinformatics
[4] Genentech,undefined
[5] Inc.,undefined
[6] Bristol Myers Squibb,undefined
来源
Scientific Data | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We performed quantitative proteomics on 60 human-derived breast cancer cell line models to a depth of ~13,000 proteins. The resulting high-throughput datasets were assessed for quality and reproducibility. We used the datasets to identify and characterize the subtypes of breast cancer and showed that they conform to known transcriptional subtypes, revealing that molecular subtypes are preserved even in under-sampled protein feature sets. All datasets are freely available as public resources on the LINCS portal. We anticipate that these datasets, either in isolation or in combination with complimentary measurements such as genomics, transcriptomics and phosphoproteomics, can be mined for the purpose of predicting drug response, informing cell line specific context in models of signalling pathways, and identifying markers of sensitivity or resistance to therapeutics.
引用
收藏
相关论文
共 54 条
  • [1] Lin NU(2012)Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network Cancer 118 5463-5472
  • [2] Perou CM(2000)Molecular portraits of human breast tumours Nature 406 747-752
  • [3] Sørlie T(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc. Natl. Acad. Sci. 98 10869-10874
  • [4] Parker JS(2009)Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes J. Clin. Oncol. 27 1160-1167
  • [5] Lehmann BD(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J. Clin. Invest. 121 2750-2767
  • [6] Willis S(2015)Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs Meta Gene 4 129-141
  • [7] Gygi SP(1999)Correlation between protein and mRNA abundance in yeast Mol. Cell. Biol. 19 1720-1730
  • [8] Rochon Y(2014)Proteogenomic characterization of human colon and rectal cancer Nature 513 382-387
  • [9] Franza BR(2017)Pharmacoproteomic characterisation of human colon and rectal cancer Mol. Syst. Biol. 13 951-644
  • [10] Aebersold R(2015)The Proteomic Landscape of Triple-Negative Breast Cancer Cell Rep. 11 630-652